ArticlePsoriasis (Auckland, N.Z.)2025
Neurofunctional Reversibility in Psoriasis Vulgaris After IL-17A Inhibition: A Resting-State fMRI and Neurocognitive Analysis.
Article in Psoriasis (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Interleukin-17A (IL-17A) drives psoriasis and central nervous system neuroinflammation, but clinical research on whether IL-17A-targeted biotherapy modulates brain activity to improve neuropsychiatric outcomes in psoriasis is lacking. This study aims to investigate brain functional changes, cognitive impairment, and the effects of IL-17A monoclonal antibody therapy in psoriasis vulgaris. Patients and methods: Regular secukinumab treatment. Meanwhile, 20 healthy controls (HCs) matched in age and gender were enrolled. The patients underwent functional magnetic resonance imaging (fMRI) before treatment and 48 weeks after treatment. The healthy controls also had fMRI scans. It assessed clinical data, cognition/neuropsych status (MoCA, SDS, SAS), disease severity/quality of Life (PASI/DLQI), and brain function via rs-fMRI (ALFF/ReHo). Results: Compared to healthy controls, the psoriasis vulgaris patients showed increased ALFF in the frontal lobe, as well as increased frontal ReHo. The treatment group showed signal recovery in some brain regions. Patients before treatment had lower MoCA scores vs controls ( Conclusion: Psoriasis is associated with brain dysfunction and neuropsychiatric symptoms. IL-17A antibody therapy improves skin symptoms, restores brain function, and alleviates neuropsychiatric issues vs untreated patients, supporting multidimensional treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.